Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Abbott Japan Co.,Ltd | INDUSTRY |
| Eisai Co., Ltd. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the long-term safety of subcutaneous (SC) self-injections (by the subject or subject's family member) of adalimumab in adult Japanese subjects with Rheumatoid Arthritis in an open-label study.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Adalimumab | Experimental | Adalimumab 40 mg or 80 mg (same dose subject was receiving in preceding Study M03-651 [NCT 00235872]) subcutaneously (sc) administered every other week (eow) until approval of adalimumab in Japan |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Adalimumab | Biological | 40 mg or 80 mg every other week (eow), subcutaneous (sc), self-injection |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Subjects With American College of Rheumatology (ACR) Criteria Improvement of at Least 20%, 50%, and 70% (ACR20/50/70 Responders, Respectively) | Number of responders with ACR criteria improvement consisting of 20%, 50%, and 70% (ACR20, ACR50, and ACR70, respectively) reduction in tender or swollen joint counts (TJC or SJC, respectively) and 20%, 50%, and 70% improvement, respectively, in 3 of the following 5 criteria: [1] physician's global assessment of disease activity (PGA), [2] subject's assessment of disease activity, [3] subject's assessment of pain, [4] subject's assessment of physical disability via a health assessment questionnaire disability index(HAQ-DI), and [5] C-reactive protein (CRP) at each visit. | Every 4 weeks up to Week 24 and every 12 weeks thereafter until study completion or discontinuation (Final value) |
| Measure | Description | Time Frame |
|---|---|---|
| Mean Change From Baseline in Tender Joint Count (TJC; Max = 68), a Component of the ACR Criteria, by Visit | Mean change from baseline (for subjects without rescue treatment, baseline is from Study M02-575 [NCT 00647491]; for subjects with rescue treatment, baseline is from Study M03-651 [NCT 00235872]) in TJC (max = 68), a component of the ACR criteria, by visit | Every 4 weeks up to Week 24 and every 12 weeks thereafter until study completion or discontinuation (Final value) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Shigeki Hashimoto, PhD | Abbott Japan | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Aichi | Japan | |||||
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Adalimumab 40 mg or 80 mg Every Other Week (Eow) | Adalimumab 40 mg or 80 mg (same dose subject was receiving in preceding Study M03-651 [NCT00235872]) subcutaneously (sc) eow until approval of adalimumab in Japan |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Adalimumab 40 mg or 80 mg Every Other Week (Eow) | Adalimumab 40 mg or 80 mg (same dose subject was receiving in preceding Study M03-651 [NCT00235872]) subcutaneously (sc) eow until approval of adalimumab in Japan |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Subjects With American College of Rheumatology (ACR) Criteria Improvement of at Least 20%, 50%, and 70% (ACR20/50/70 Responders, Respectively) | Number of responders with ACR criteria improvement consisting of 20%, 50%, and 70% (ACR20, ACR50, and ACR70, respectively) reduction in tender or swollen joint counts (TJC or SJC, respectively) and 20%, 50%, and 70% improvement, respectively, in 3 of the following 5 criteria: [1] physician's global assessment of disease activity (PGA), [2] subject's assessment of disease activity, [3] subject's assessment of pain, [4] subject's assessment of physical disability via a health assessment questionnaire disability index(HAQ-DI), and [5] C-reactive protein (CRP) at each visit. | Analysis was based on observed data. | Posted | Number | participants | Every 4 weeks up to Week 24 and every 12 weeks thereafter until study completion or discontinuation (Final value) |
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Adalimumab 40 mg or 80 mg Every Other Week (Eow) | Adalimumab 40 mg or 80 mg (same dose subject was receiving in preceding Study M03-651 [NCT00235872]) subcutaneously (sc) eow until approval of adalimumab in Japan |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Angina pectoris | Cardiac disorders |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anaemia | Blood and lymphatic system disorders |
Due to the small population, statistical tests were not performed.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Global Medical Services | Abbott | 1-800-633-9110 |
Not provided
| ID | Term |
|---|---|
| D001172 | Arthritis, Rheumatoid |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000068879 | Adalimumab |
| ID | Term |
|---|---|
| D061067 | Antibodies, Monoclonal, Humanized |
| D000911 | Antibodies, Monoclonal |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Mean Change From Baseline in Swollen Joint Count (SJC, Max = 66), a Component of the ACR Criteria by Visit | Mean change from baseline (for subjects without rescue treatment, baseline is from Study M02-575 [NCT 00647491]; for subjects with rescue treatment, baseline is from Study M03-651 [NCT 00235872]) in SJC (max = 66), a component of the ACR criteria, by visit | Every 4 weeks up to Week 24 and every 12 weeks thereafter until study completion or discontinuation (final value) |
| Mean Change From Baseline in Physician's Global Assessment of Disease Activity (PGA) Using a Visual Analog Scale (0 - 100 mm With 100 mm Being the Worst Assessment), a Component of the ACR Criteria, by Visit | Mean change from baseline (for subjects without rescue treatment, baseline is from Study M02-575 [NCT 00647491]; for subjects with rescue treatment, baseline is from Study M03-651 [NCT 00235872]) in PGA (a visual analog scale from 0 - 100 mm with 100 mm being the worst case), a component of the ACR criteria, by visit | Every 4 weeks weeks up to Week 24 and every 12 weeks thereafter until study completion or discontinuation (Final value) |
| Mean Change From Baseline in Subject's Global Assessment of Disease Activity Using a Visual Analog Scale (0 - 100 mm With 100 mm Being the Worst Assessment), a Component of the ACR Criteria, by Visit | mean change from baseline (for subjects without rescue treatment, baseline is from Study M02-575 [NCT 00647491]; for subjects with rescue treatment, baseline is from Study M03-651 [NCT 00235872]) in subjects global assessment of disease activity (a visual analog scale from 0 - 100 mm with 100 mm being the worst case), a component of the ACR criteria, by visit | Every 4 weeks up to Week 24 and every 12 weeks thereafter until study completion or discontinuation (Final value) |
| Mean Change From Baseline in Subject's Assessment of Pain Using a Visual Analog Scale (0 - 100 mm With 100 mm Being the Worst Pain), a Component of the ACR Criteria, by Visit | Mean change from baseline (for subjects without rescue treatment, baseline is from Study M02-575 [NCT 00647491]; for subjects with rescue treatment, baseline is from Study M03-651 [NCT 00235872]) in subject's assessment of pain (on a visual analog scale from 0 - 100 mm with 100 mm being the worst pain), a component of the ACR criteria, by visit | Every 4 weeks up to Week 24 and every 12 weeks thereafter until study completion or discontinuation (Final Value) |
| Mean Change From Baseline in Disability Index of the Health Assessment Questionnaire (HAQ), a Component of the ACR Criteria, by Visit | Mean change from baseline (for subjects without rescue treatment, baseline is from Study M02-575 [NCT 00647491]; for subjects with rescue treatment, baseline is from Study M03-651 [NCT 00235872]) in disability index of the HAQ (includes 20 questions assessing physical function in 8 domains. The questions are evaluated on a scale from 0 - 3 to measure the ability to perform certain activities [0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do so]), a component of the ACR criteria by visit | Every 4 weeks up to Week 24 and every 12 weeks thereafter until study completion or discontinuation (final value) |
| Mean Change From Baseline in C-reactive Protein (CRP), a Component of the ACR Criteria by Visit | Mean change from baseline(for subjects without rescue treatment, baseline is from Study M02-575 [NCT 00647491]; for subjects with rescue treatment, baseline is from Study M03-651 [NCT 00235872]) in CRP (mg/dL), a component of the ACR criteria, by visit | Every 4 weeks up to Week 24 and every 12 weeks thereafter until study completion or discontinuation (Final Value) |
| Presence of Morning Stiffness by Visit | The number of subjects with morning stiffness at each visit among those who had morning stiffness at baseline (64). | Every 4 weeks up to Week 24 and every 12 weeks thereafter until study completion or discontinuation (final value) |
| Duration (Minutes) of the Presence of Morning Stiffness by Visit | Mean change from baseline (for subjects without rescue treatment, baseline is from Study M02-575 [NCT 00647491]; for subjects with rescue treatment, baseline is from Study M03-651 [NCT 00235872]) in the duration (minutes) of stiffness in the morning. | Every 4 weeks up to Week 24 and every 12 weeks thereafter until study completion or discontinuation (final value) |
| Chiba |
| Japan |
| Fukuoka | Japan |
| Gunma | Japan |
| Hokkaido | Japan |
| Hyōgo | Japan |
| Ibaraki | Japan |
| Kanagawa | Japan |
| Miyagi | Japan |
| Nagano | Japan |
| Okayama | Japan |
| Osaka | Japan |
| Saitama | Japan |
| Shizuoka | Japan |
| Tokyo | Japan |
| Toyama | Japan |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
Adalimumab 40 mg or 80 mg (same dose subject was receiving in preceding Study M03-651 [NCT00235872]) subcutaneously (sc) eow until approval of adalimumab in Japan |
|
|
| Secondary | Mean Change From Baseline in Tender Joint Count (TJC; Max = 68), a Component of the ACR Criteria, by Visit | Mean change from baseline (for subjects without rescue treatment, baseline is from Study M02-575 [NCT 00647491]; for subjects with rescue treatment, baseline is from Study M03-651 [NCT 00235872]) in TJC (max = 68), a component of the ACR criteria, by visit | Posted | Mean | Standard Deviation | TJC | Every 4 weeks up to Week 24 and every 12 weeks thereafter until study completion or discontinuation (Final value) |
|
|
|
| Secondary | Mean Change From Baseline in Swollen Joint Count (SJC, Max = 66), a Component of the ACR Criteria by Visit | Mean change from baseline (for subjects without rescue treatment, baseline is from Study M02-575 [NCT 00647491]; for subjects with rescue treatment, baseline is from Study M03-651 [NCT 00235872]) in SJC (max = 66), a component of the ACR criteria, by visit | Posted | Mean | Standard Deviation | SJC | Every 4 weeks up to Week 24 and every 12 weeks thereafter until study completion or discontinuation (final value) |
|
|
|
| Secondary | Mean Change From Baseline in Physician's Global Assessment of Disease Activity (PGA) Using a Visual Analog Scale (0 - 100 mm With 100 mm Being the Worst Assessment), a Component of the ACR Criteria, by Visit | Mean change from baseline (for subjects without rescue treatment, baseline is from Study M02-575 [NCT 00647491]; for subjects with rescue treatment, baseline is from Study M03-651 [NCT 00235872]) in PGA (a visual analog scale from 0 - 100 mm with 100 mm being the worst case), a component of the ACR criteria, by visit | Posted | Mean | Standard Deviation | mm on a scale | Every 4 weeks weeks up to Week 24 and every 12 weeks thereafter until study completion or discontinuation (Final value) |
|
|
|
| Secondary | Mean Change From Baseline in Subject's Global Assessment of Disease Activity Using a Visual Analog Scale (0 - 100 mm With 100 mm Being the Worst Assessment), a Component of the ACR Criteria, by Visit | mean change from baseline (for subjects without rescue treatment, baseline is from Study M02-575 [NCT 00647491]; for subjects with rescue treatment, baseline is from Study M03-651 [NCT 00235872]) in subjects global assessment of disease activity (a visual analog scale from 0 - 100 mm with 100 mm being the worst case), a component of the ACR criteria, by visit | Posted | Mean | Standard Deviation | mm on a scale | Every 4 weeks up to Week 24 and every 12 weeks thereafter until study completion or discontinuation (Final value) |
|
|
|
| Secondary | Mean Change From Baseline in Subject's Assessment of Pain Using a Visual Analog Scale (0 - 100 mm With 100 mm Being the Worst Pain), a Component of the ACR Criteria, by Visit | Mean change from baseline (for subjects without rescue treatment, baseline is from Study M02-575 [NCT 00647491]; for subjects with rescue treatment, baseline is from Study M03-651 [NCT 00235872]) in subject's assessment of pain (on a visual analog scale from 0 - 100 mm with 100 mm being the worst pain), a component of the ACR criteria, by visit | Posted | Mean | Standard Deviation | mm on a scale | Every 4 weeks up to Week 24 and every 12 weeks thereafter until study completion or discontinuation (Final Value) |
|
|
|
| Secondary | Mean Change From Baseline in Disability Index of the Health Assessment Questionnaire (HAQ), a Component of the ACR Criteria, by Visit | Mean change from baseline (for subjects without rescue treatment, baseline is from Study M02-575 [NCT 00647491]; for subjects with rescue treatment, baseline is from Study M03-651 [NCT 00235872]) in disability index of the HAQ (includes 20 questions assessing physical function in 8 domains. The questions are evaluated on a scale from 0 - 3 to measure the ability to perform certain activities [0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do so]), a component of the ACR criteria by visit | Posted | Mean | Standard Deviation | units on a scale | Every 4 weeks up to Week 24 and every 12 weeks thereafter until study completion or discontinuation (final value) |
|
|
|
| Secondary | Mean Change From Baseline in C-reactive Protein (CRP), a Component of the ACR Criteria by Visit | Mean change from baseline(for subjects without rescue treatment, baseline is from Study M02-575 [NCT 00647491]; for subjects with rescue treatment, baseline is from Study M03-651 [NCT 00235872]) in CRP (mg/dL), a component of the ACR criteria, by visit | Posted | Mean | Standard Deviation | mg/dL | Every 4 weeks up to Week 24 and every 12 weeks thereafter until study completion or discontinuation (Final Value) |
|
|
|
| Secondary | Presence of Morning Stiffness by Visit | The number of subjects with morning stiffness at each visit among those who had morning stiffness at baseline (64). | Subjects were included in this analysis if they had morning stiffness at baseline. Analysis results are as-observed. | Posted | Number | participants | Every 4 weeks up to Week 24 and every 12 weeks thereafter until study completion or discontinuation (final value) |
|
|
|
| Secondary | Duration (Minutes) of the Presence of Morning Stiffness by Visit | Mean change from baseline (for subjects without rescue treatment, baseline is from Study M02-575 [NCT 00647491]; for subjects with rescue treatment, baseline is from Study M03-651 [NCT 00235872]) in the duration (minutes) of stiffness in the morning. | Subjects were included in this analysis if they had morning stiffness at baseline. Analysis results are as-observed. | Posted | Mean | Standard Deviation | minutes | Every 4 weeks up to Week 24 and every 12 weeks thereafter until study completion or discontinuation (final value) |
|
|
|
| 20 |
| 88 |
| 84 |
| 88 |
| Atrial thrombosis | Cardiac disorders |
|
| Cardiac failure | Cardiac disorders |
|
| Vertigo positional | Ear and labyrinth disorders |
|
| Cataract | Eye disorders |
|
| Enterocolitis | Gastrointestinal disorders |
|
| Ileus | Gastrointestinal disorders |
|
| Cellulitis | Infections and infestations |
|
| Enteritis infectious | Infections and infestations |
|
| Herpes zoster | Infections and infestations |
|
| Urinary tract infection | Infections and infestations |
|
| Clavicle fracture | Injury, poisoning and procedural complications |
|
| Joint dislocation | Injury, poisoning and procedural complications |
|
| Ligament rupture | Injury, poisoning and procedural complications |
|
| Tendon rupture | Injury, poisoning and procedural complications |
|
| Joint destruction | Musculoskeletal and connective tissue disorders |
|
| Knee deformity | Musculoskeletal and connective tissue disorders |
|
| Rheumatoid arthritis | Musculoskeletal and connective tissue disorders |
|
| Malignant ascites | Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
| Ovarian cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
| Renal failure acute | Renal and urinary disorders |
|
| Asthma | Respiratory, thoracic and mediastinal disorders |
|
| Vertigo | Ear and labyrinth disorders |
|
| Constipation | Gastrointestinal disorders |
|
| Dental caries | Gastrointestinal disorders |
|
| Diarrhoea | Gastrointestinal disorders |
|
| Abdominal pain upper | Gastrointestinal disorders |
|
| Gingivitis | Gastrointestinal disorders |
|
| Haemorrhoids | Gastrointestinal disorders |
|
| Stomatitis | Gastrointestinal disorders |
|
| Nausea | Gastrointestinal disorders |
|
| Vomiting | Gastrointestinal disorders |
|
| Adverse drug reaction | General disorders |
|
| Hepatic function abnormal | Hepatobiliary disorders |
|
| Seasonal allergy | Immune system disorders |
|
| Nasopharyngitis | Infections and infestations |
|
| Bronchitis | Infections and infestations |
|
| Upper respiratory tract infection | Infections and infestations |
|
| Pharyngitis | Infections and infestations |
|
| Tinea infection | Infections and infestations |
|
| Contusion | Injury, poisoning and procedural complications |
|
| Fall | Injury, poisoning and procedural complications |
|
| Antinuclear antibody positive | Investigations |
|
| DNA antibody positive | Investigations |
|
| Protein urine present | Investigations |
|
| Back pain | Musculoskeletal and connective tissue disorders |
|
| Rheumatoid arthritis | Musculoskeletal and connective tissue disorders |
|
| Headache | Nervous system disorders |
|
| Insomnia | Psychiatric disorders |
|
| Cough | Respiratory, thoracic and mediastinal disorders |
|
| Upper respiratory tract inflammation | Respiratory, thoracic and mediastinal disorders |
|
| Rhinorrhoea | Respiratory, thoracic and mediastinal disorders |
|
| Pharyngolaryngeal pain | Respiratory, thoracic and mediastinal disorders |
|
| Pharyngolaryngeal discomfort | Respiratory, thoracic and mediastinal disorders |
|
| Pruritus | Skin and subcutaneous tissue disorders |
|
| Rash | Skin and subcutaneous tissue disorders |
|
| Eczema | Skin and subcutaneous tissue disorders |
|
| Erythema | Skin and subcutaneous tissue disorders |
|
| Hyperkeratosis | Skin and subcutaneous tissue disorders |
|
Disclosure agreements vary; most restrictive agreement states Medical Institution shall not disclose materials/information disclosed by Abbott Japan in connection with the Clinical Research, or information obtained by conducting the Clinical Research, to third parties without Abbott Japan's prior written approval. When Medical Institution intends to publish information obtained by conducting the Clinical Research, Medical Institution shall obtain Abbott Japan's prior written approval.
| D003240 |
| Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D007162 |
| Immunoproteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |
| Title | Measurements |
|---|---|
|
| Week 8 |
|
| Week 12 |
|
| Week 16 |
|
| Week 20 |
|
| Week 24 |
|
| Week 36 |
|
| Week 48 |
|
| Week 60 |
|
| Week 72 |
|
| Week 84 |
|
| Week 96 |
|
| Week 108 |
|
| Week 120 |
|
| Week 132 |
|
| Final |
|
| Title | Measurements |
|---|---|
|
| Week 8 |
|
| Week 12 |
|
| Week 16 |
|
| Week 20 |
|
| Week 24 |
|
| Week 36 |
|
| Week 48 |
|
| Week 60 |
|
| Week 72 |
|
| Week 84 |
|
| Week 96 |
|
| Week 108 |
|
| Week 120 |
|
| Week 132 |
|
| Final |
|
| Title | Measurements |
|---|---|
|
| Week 8 |
|
| Week 12 |
|
| Week 16 |
|
| Week 20 |
|
| Week 24 |
|
| Week 36 |
|
| Week 48 |
|
| Week 60 |
|
| Week 72 |
|
| Week 84 |
|
| Week 96 |
|
| Week 108 |
|
| Week 120 |
|
| Week 132 |
|
| Final |
|
| Title | Measurements |
|---|---|
|
| Week 8 |
|
| Week 12 |
|
| Week 16 |
|
| Week 20 |
|
| Week 24 |
|
| Week 36 |
|
| Week 48 |
|
| Week 60 |
|
| Week 72 |
|
| Week 84 |
|
| Week 96 |
|
| Week 108 |
|
| Week 120 |
|
| Week 132 |
|
| Final |
|
| Title | Measurements |
|---|---|
|
| Week 8 |
|
| Week 12 |
|
| Week 16 |
|
| Week 20 |
|
| Week 24 |
|
| Week 36 |
|
| Week 48 |
|
| Week 60 |
|
| Week 72 |
|
| Week 84 |
|
| Week 96 |
|
| Week 108 |
|
| Week 120 |
|
| Week 132 |
|
| Final |
|
| Title | Measurements |
|---|---|
|
| Week 8 |
|
| Week 12 |
|
| Week 16 |
|
| Week 20 |
|
| Week 24 |
|
| Week 36 |
|
| Week 48 |
|
| Week 60 |
|
| Week 72 |
|
| Week 84 |
|
| Week 96 |
|
| Week 108 |
|
| Week 120 |
|
| Week 132 |
|
| Final |
|
| Title | Measurements |
|---|---|
|
| Week 8 |
|
| Week 12 |
|
| Week 16 |
|
| Week 20 |
|
| Week 24 |
|
| Week 36 |
|
| Week 48 |
|
| Week 60 |
|
| Week 72 |
|
| Week 84 |
|
| Week 96 |
|
| Week 108 |
|
| Week 120 |
|
| Week 132 |
|
| Final |
|
| Title | Measurements |
|---|
|
| Week 12 |
|
| Week 16 |
|
| Week 20 |
|
| Week 24 |
|
| Week 36 |
|
| Week 48 |
|
| Week 60 |
|
| Week 72 |
|
| Week 84 |
|
| Week 96 |
|
| Week 108 |
|
| Week 120 |
|
| Week 132 |
|
| Final |
|
| Title | Measurements |
|---|---|
|
| Week 8 |
|
| Week 12 |
|
| Week 16 |
|
| Week 20 |
|
| Week 24 |
|
| Week 36 |
|
| Week 48 |
|
| Week 60 |
|
| Week 72 |
|
| Week 84 |
|
| Week 96 |
|
| Week 108 |
|
| Week 120 |
|
| Week 132 |
|
| Final |
|